RSS   Newsletter   Contact   Advertise with us
Post Online Media

Axovant Sciences appoints David Hung as CEO

AxovantAxovant Sciences Ltd., a clinical-stage biopharmaceutical company, announced that David Hung has been named chief executive officer.

Dr. Hung founded Medivation in 2003 and served as President and CEO through its acquisition by Pfizer in 2016.

Prior to his founding and leadership experiences with Medivation, Dr. Hung served as President and CEO at ProDuct Health, Inc., from 1999 until its acquisition by Cytyc Corporation in 2001, and was Vice President of New Projects as well as Lead Discovery and Development at Chiron Corporation.

Dr. Hung completed clinical fellowships in hematology, oncology, and transfusion medicine as well as basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine.

He received an MD Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an AB in Biology summa cum laude from Harvard College.


More inside POST

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy